US 9803021
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 9803021 (CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities) held by The Regents of the University of California expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/212, A61K38/215